Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novozymes Buys India's Biocon
July 23, 2007
| A version of this story appeared in
Volume 85, Issue 30
Denmark-based Novozymes has agreed to acquire the enzyme activities of Biocon, of Bangalore, India, for $115 million. The buy will strengthen Novozymes' product portfolio in sales of enzymes for the juice and wine industries with the addition of Biocon's pectinase product line. Enzymes now account for 12% of Biocon's turnover, but they were the first business the firm got into when it was formed in 1978. The Indian company plans to focus on its expanding business in active pharmaceutical ingredients, biologicals, and proprietary molecules. Novozymes currently is establishing local R&D facilities in Bangalore.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X